4 unchanged sentences
Number Date Filed
−Removed: 10.1* Amendment dated September 29 , 2021 to Contract by and between the National Institutes of Health and the registrant effective as of July 30, 2020, as amended September 28, 2020 , February 18, 2021 , and May 1 0 , 2021 .
−Removed: Filed herewith
−Removed: 10.2 Fourth Amendment to Loan and Security Agreement, dated as of August 2, 2021, between Fluidigm Corporation and Silicon Valley Bank.
+Added: 3.1 Eighth Amended and Restated Certificate of Incorporation filed on February 15, 2011.
10-K 3.1 3/28/2011
+Added: 3.2 Amended and Restated Bylaws of Standard BioTools Inc.
+Added: S-8 4.8 4/1/2022
+Added: 3.3 Certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation.
+Added: S-8 4.3 4/1/2022
+Added: 3.4 Certificate of Designation of Rights, Preferences and Privileges of Series A Participating Preferred Stock .
+Added: 8-K 3.1 11/22/2016
+Added: 3.5 Certificate of Elimination of Series A Participating Preferred Stock.
+Added: 8-K 3.1 8/2/2017
+Added: 3.6 Certificate of Designations of Rights, Preferences and Privileges of Series B-1 Convertible Preferred Stock.
+Added: 8-K 3.6 4/5/2022
+Added: 3.7 Certificate of Designations of Rights, Preferences and Privileges of Series B-2 Convertible Preferred Stock.
+Added: 8-K 3.7 4/5/2022
+Added: 10.1 Series B-1 Loan Agreement, dated as of January 23, 2022, by and among Fluidigm Corporation, Casdin Partners Master Fund, L.P., and Casdin Private Growth Equity Fund II, L.P.
+Added: 8-K/A 10.1 2/11/2022
+Added: 10.2 Series B-2 Loan Agreement, dated as of January 23, 2022, by and among Fluidigm Corporation, Viking Global Opportunities Illiquid Investments Sub-Master LP, and Viking Global Opportunities Drawdown (Aggregator) LP.
+Added: 8-K 10.2 1/24/2022
+Added: 10.3 Series B-1 Convertible Preferred Stock Purchase Agreement, dated as of January 23, 2022, by and among Fluidigm Corporation, Casdin Private Growth Equity Fund II, L.P., and Casdin Partners Master Fund, L.P.
+Added: 10.4 Series B-2 Convertible Preferred Stock Purchase Agreement, dated as of January 23, 2022, by and among Fluidigm Corporation, Viking Global Opportunities Illiquid Investments Sub-Master LP, and Viking Global Opportunities Drawdown (Aggregator) LP.
+Added: 10.5 Registration Rights Agreement, dated as of January 23, 2022, by and between Fluidigm Corporation, Casdin Private Growth Equity Fund II, L.P., Casdin Partners Master Fund, L.P., Viking Global Opportunities Illiquid Investments Sub-Master LP, and Viking Global Opportunities Drawdown (Aggregator) LP.
+Added: 8-K 10.5 1/24/2022
+Added: 10.6+ Stephen Christopher Linthwaite Transition Agreement and Release.
+Added: 8-K 10.6 1/24/2022
+Added: 10.7+ Michael Egholm Offer Letter .
+Added: 8-K 10.7 1/24/2022
+Added: 10.8 Indemnification Agreement, dated January 23, 2022, by and between the Company and Michael Egholm.
+Added: 8-K 10.8 1/24/2022
+Added: 10.9+ Hanjoon Alex Kim Offer Letter .
+Added: 8-K 10.9 1/24/2022
+Added: 10.10+ Standard BioTools 2022 Inducement Equity Incentive Plan .
+Added: S-8 4.9 4/1/2022
+Added: 10.11+ Form of Notice of Stock Option Grant and Stock Option Agreement under the 2022 Inducement Equity Incentive Plan .
+Added: S-8 99.1 4/1/2022
+Added: 10.12+ Form of Notice of Restricted Stock Unit Grant and Restricted Stock Unit Agreement under the 2022 Inducement Equity Incentive Plan .
+Added: S-8 99.2 4/1/2022
+Added: 10.13+ Form of Retention Letter.
+Added: 8-K 10.10 1/24/2022
+Added: 10.14 Default Waiver and Consent to Loan and Security Agreement, dated March 4, 2022, between the Company and Silicon Valley Bank.
+Added: 10-K 10.19F 3/8/2022
+Added: 10.15 Letter Agreement dated March 25, 2022 .
+Added: 8-K 10.1 3/28/2022
+Added: 10.16 Support Agreement, dated March 29, 2022, by and among Fluidigm Corporation and Caligan Partners LP and certain of its affiliates .
+Added: 8-K 10.1 3/29/2022
+Added: Number Description Incorporated
+Added: From Form Incorporated
+Added: Number Date Filed
31.1 Certification Pursuant to 18 U.S.C.
18 unchanged sentences
* Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv).
+Added: + Indicates management contract or compensatory plan, contract, or arrangement.
(1) In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No.
3 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: FLUIDIGM CORPORATION
−Removed: November 8, 2021 By:
−Removed: /s/ Stephen Christopher Linthwaite
−Removed: Stephen Christopher Linthwaite
−Removed: President and Chief Executive Officer
−Removed: November 8, 2021 By:
+Added: STANDARD BIOTOOLS INC.
+Added: May 9, 2022 By:
+Added: /s/ Michael Egholm
+Added: Michael Egholm
+Added: Chief Executive Officer and President
+Added: May 9, 2022 By:
/s/ Vikram Jog
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.